CPED1: A Potential Drug Target for Cancer (G79974)

Target Name: CPED1

NCBI ID: G79974

CPED1

CPED1: A Potential Drug Target for Cancer

Cancer is one of the leading causes of death worldwide, and the development of new treatments is crucial in reducing cancer incidence and mortality. One potential drug target in the cancer field is the proteinCPED1 (Cytosine Phosphine-Ethylenediamine), also known as FLJ26813. This protein is a key player in the cell cycle and has been linked to the regulation of various cellular processes, including cell growth, apoptosis, and DNA replication. In this article, we will discuss the biology of CPED1, its potential as a drug target, and the research being conducted to target this protein in cancer treatment.

The Importance of the Cell Cycle
The cell cycle is the process by which cells grow, divide, and replicate their genetic material. The cell cycle is regulated by a complex network of proteins, includingCPED1, which plays a critical role in the regulation of DNA replication and the metaphase transition.

During the G1 phase of the cell cycle,CPED1 is involved in the removal of damaged DNA from the cell and the initiation of the S-phase. During S-phase,CPED1 is responsible for the proper duplication of the double helix and the formation of the two daughter chromatin. In addition,CPED1 is also involved in the regulation of the anaphase transition, which is the stage of cell division where the two daughter chromatin plates are separated and the cell divides.

In addition to its role in regulating the cell cycle,CPED1 has also been linked to the regulation of apoptosis, which is the process by which cells undergo programmed cell death. During times of stress, such as UV exposure, chemical insults, or infections,CPED1 has been shown to play a role in the regulation of apoptosis to protect the cell from injury.

CPED1 as a Drug Target
The potential use of CPED1 as a drug target comes from its unique structure and the various functions it is involved in. Because CPED1 is a protein that can be targeted by small molecules, researchers have been able to develop a number of compounds that can inhibit its activity.

One of the most promising compounds currently in development is a small molecule called CPI-0610, which is a inhibitor of the kinase that activates CPED1. CPI-0610 has been shown to be effective in cell experiments and has the potential to be a useful treatment for various cancers.

Another compound that is being developed as a potential drug target for CPED1 is a peptide called P4. P4 is a small protein that is composed of four amino acids and is located in the same region of the cell cycle as CPED1. P4 has been shown to be a good candidate for a drug because it is able to interact with CPED1 and inhibit its activity.

Research on CPED1 as a drug target is still in its early stages, but it holds great promise as a new treatment option for various cancers.

Conclusion
CPED1 is a protein that is involved in the regulation of the cell cycle and has been linked to the regulation of various cellular processes, including cell growth, apoptosis, and DNA replication. As a result, it is a potential drug target for cancer treatment. The development of compounds that can inhibit the activity of CPED1 is an exciting area of research and holds great promise for the future of cancer treatment.

Protein Name: Cadherin Like And PC-esterase Domain Containing 1

The "CPED1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPED1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets